Arbutus Biopharma (ABUS)

Executive Summary

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. More Details


Revenue is forecast to grow 46.79% per year

Earnings have grown 7.6% per year over the past 5 years

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Snowflake Analysis

Flawless balance sheet with limited growth.

Similar Companies

Search for a company to compare.